๐ก Get more than just numbers. Subscribe to access AI-powered analysis of company reports โ key trends and metrics in a simple, easy-to-understand format.
Estimate
P/E
30.2
EPS
17.14
Beta
0.305
Growth
Revenue, YoY
12.45%
Net income, YoY
6.48%
FCF, YoY
9.25%
Forecast
P/E (FWD)
24.3
EPS (FWD)
21.292
About the company
Ticker
VRTX
ISIN
US92532F1003
Country
United States of America
Sector (GICS)
Healthcare
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Vertex Pharmaceuticals Incorporated (VRTX) operate in?
Vertex Pharmaceuticals Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vertex Pharmaceuticals Incorporated (VRTX) current stock price?
As of the latest data, Vertex Pharmaceuticals Incorporated stock price is $518.35, with a previous close of $525.73. Vertex Pharmaceuticals Incorporated lost -$7.38 in the last trading session, representing a -1.4% loss.
What is Vertex Pharmaceuticals Incorporated (VRTX) current market capitalization?
Vertex Pharmaceuticals Incorporated market cap is approximately 131.30 billion.
What is Vertex Pharmaceuticals Incorporated (VRTX) Earnings Per Share (EPS)?
The trailing EPS is $17.14, and the forward EPS is $21.29.
What is Vertex Pharmaceuticals Incorporated (VRTX) Price-to-Earnings (P/E) ratio?
Vertex Pharmaceuticals Incorporated current P/E ratio is 30.24, with a forward P/E of 24.34.
What is Vertex Pharmaceuticals Incorporated (VRTX) EBITDA?
Vertex Pharmaceuticals Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.39 billion.
Does Vertex Pharmaceuticals Incorporated (VRTX) pay dividends?
No. Vertex Pharmaceuticals Incorporated does not pay a dividend.
How did Vertex Pharmaceuticals Incorporated (VRTX) perform in its most recent earnings report?
In the last report (June 30, 2026), Vertex Pharmaceuticals Incorporated posted an EPS surprise of 1.2% and a revenue surprise of 3.43%.
What is Vertex Pharmaceuticals Incorporated (VRTX) beta (volatility) score?
Vertex Pharmaceuticals Incorporated has a beta of 0.305, indicating lower volatility than the overall market.
